TDM Introduction - Precision Dosing 101
- Therapeutic Drug Monitoring (TDM): Optimizing drug therapy by measuring drug concentrations in biological fluids.
- Goal: Maintain concentrations within a target therapeutic window to ensure efficacy & minimize toxicity.
- Crucial for drugs with:
- Narrow Therapeutic Index (NTI)
- Significant pharmacokinetic variability
- Concentration-related therapeutic/toxic effects
- Relies on understanding PK/PD relationships.
⭐ TDM aims to individualize dosage regimens by maintaining plasma drug concentrations within a target therapeutic range.
Indications for TDM - Narrow Escape Artists
TDM is vital for "Narrow Escape Artists" - drugs demanding precise dosing. Key indications include:
⭐ TDM is crucial for drugs where clinical effect is difficult to monitor and there's a good correlation between drug concentration and effect/toxicity.
Pharmacokinetics in TDM - Drug's Body Journey
- LADME: Core processes (Liberation, Absorption, Distribution, Metabolism, Excretion).
- Key Parameters:
- Bioavailability (F): Fraction of administered drug reaching systemic circulation.
- Volume of Distribution ($V_d$): Apparent volume into which a drug distributes. $V_d = Dose / C_0$.
- Clearance (CL): Volume of plasma cleared of drug per unit time. $CL = k \times V_d$.
- Half-life ($t_{1/2}$): Time for drug concentration to decrease by half. $t_{1/2} = (0.693 \times V_d) / CL$.
- Steady State ($C_{ss}$): Achieved when rate of drug administration equals rate of elimination.
- Formula: $C_{ss} = (Dose \times F) / (CL \times \tau)$, where $\tau$ is dosing interval.
- Therapeutic Window: Range between Minimum Effective Concentration (MEC) & Minimum Toxic Concentration (MTC).
- Sampling Times: Crucial for interpretation.
- Trough level: Just before next dose (lowest concentration).
- Peak level: After drug distribution (highest concentration).
⭐ Steady state concentration ($C_{ss}$) is usually achieved after 4-5 elimination half-lives of the drug.
oka
TDM Process - Sample, Test, Adjust
⭐ For most drugs, trough (pre-dose) concentrations are measured to assess therapeutic efficacy and minimize toxicity risk.
- Key Considerations:
- Steady State: Achieved after 3-5 drug half-lives.
- Sample Type: Serum or plasma typically used.
- Assay Specificity & Precision: Crucial for reliable results.
Key Monitored Drugs - The TDM VIP List
| Drug | Therapeutic Range | Toxic Level | Key Point |
|---|---|---|---|
| Digoxin | 0.8-2.0 ng/mL | >2.4 ng/mL | Hypokalemia ↑ toxicity; visual changes |
| Lithium | 0.6-1.2 mEq/L | >1.5 mEq/L | Monitor renal, thyroid; tremor, NDI |
| Phenytoin | 10-20 mcg/mL | >20 mcg/mL | Saturable kinetics; nystagmus, ataxia |
| Vancomycin | Trough: 10-20 mcg/mL | >20 mcg/mL | Nephro/ototoxicity; Red Man Syndrome |
| Aminoglycosides | Peak/Trough specific | Dose-dependent | Nephro/ototoxicity; monitor renal fxn |
| Theophylline | 10-20 mcg/mL | >20 mcg/mL | Seizures, arrhythmias; CYP interactions |
High‑Yield Points - ⚡ Biggest Takeaways
- TDM optimizes dosing by maintaining drug concentrations within the therapeutic window, preventing toxicity.
- Essential for drugs with a narrow therapeutic index (e.g., Digoxin, Lithium, Phenytoin, Theophylline).
- Correct sample timing (often trough levels just before the next dose) is paramount for accurate interpretation.
- Monitoring is most reliable at steady state (typically after 4-5 half-lives of the drug).
- Patient factors like renal/hepatic function, adherence, and drug interactions significantly influence levels.
- Key drugs also include Aminoglycosides (e.g., Gentamicin, Amikacin) and Vancomycin.
Continue reading on Oncourse
Sign up for free to access the full lesson, plus unlimited questions, flashcards, AI-powered notes, and more.
CONTINUE READING — FREEor get the app